Relates to establishing the "340B prescription drug anti-discrimination act"; prohibits pharmaceutical manufacturers and pharmacy benefit managers from discriminating against covered entities and New York state pharmacies based on participation in the drug discount program authorized by section 340B of the federal public health service act.

New York Assembly Bill A06222, known as the '340B Prescription Drug Anti-Discrimination Act,' aims to prevent pharmaceutical manufacturers and pharmacy benefit managers (PBMs) from treating certain healthcare providers and pharmacies unfairly because they participate in the federal 340B drug discount program. This program allows eligible healthcare providers to buy medications at reduced prices to serve low-income and uninsured patients. The bill seeks to ensure that these providers and pharmacies are not penalized or discriminated against for their participation in the program.

Supporters of the bill argue that it protects safety-net healthcare providers and pharmacies that serve vulnerable populations. By preventing discriminatory practices by pharmaceutical manufacturers and PBMs, the legislation aims to ensure that these providers can continue to offer affordable medications to low-income and uninsured patients. This protection is seen as essential for maintaining access to necessary healthcare services in underserved communities.

Critics, particularly from the pharmaceutical industry, contend that some providers may misuse the 340B program to increase profits rather than aid vulnerable patients. They argue that without stricter eligibility requirements and more controls on 340B pharmacy operations, the program could be exploited, leading to increased costs and reduced transparency in drug pricing. These concerns have led to calls for reforms to ensure the program's integrity and proper use.